eXoZymes Inc（EXOZ）資訊與事件EXOZeXoZymes Inc

eXoZymes Achieves Biomanufacturing Milestone with Cayman Chemical

eXoZymes announced an important validation and de-risking milestone for its cell-free biomanufacturing platform: An independent partner, Cayman Chemical, successfully ran eXoZymes' technology at pilot scale and achieved results consistent with - and in some cases exceeding - earlier internal runs. Using eXoZymes' tech transfer package, Cayman Chemical advanced the protocol from a one-liter setup to a 100-liter pilot run, operating the reaction, downstream processing, and analysis independently. During the run, the team encountered real-world conditions - including pH variation and precipitation - which often cause enzyme-based processes to fail. Despite this, the reaction continued to perform reliably and delivered strong results, ultimately producing more than 500 grams of pharma-grade N-trans-caffeoyltyramine, or NCT, at 99.6% purity, a result that is difficult to obtain in biomanufacturing without extensive purification steps. Additionally, the 99% conversion of feedstock to end product highlights a level of efficiency that is challenging to achieve and maintain in traditional biomanufacturing. With isolated high-purity NCT now produced at pilot scale, eXoZymes is actively engaging with partners interested in formulation development, product validation, and application-specific testing. The availability of high-purity material enables partners to move beyond feasibility studies and into hands-on evaluation under relevant conditions.

eXoZymes Files $50M Mixed Securities Shelf

eXoZymes files $50M mixed securities shelf